KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

AbbVie (ABBV) Return on Capital Employed (2016 - 2026)

AbbVie has reported Return on Capital Employed over the past 13 years, most recently at 16.63% for Q4 2025.

  • Quarterly Return on Capital Employed rose 754.0% to 16.63% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 16.63% through Dec 2025, up 754.0% year-over-year, with the annual reading at 16.52% for FY2025, 702.0% up from the prior year.
  • Return on Capital Employed was 16.63% for Q4 2025 at AbbVie, up from 9.4% in the prior quarter.
  • Over five years, Return on Capital Employed peaked at 16.93% in Q2 2023 and troughed at 9.09% in Q4 2024.
  • The 5-year median for Return on Capital Employed is 13.86% (2021), against an average of 13.63%.
  • Year-over-year, Return on Capital Employed plummeted -842bps in 2021 and then skyrocketed 754bps in 2025.
  • A 5-year view of Return on Capital Employed shows it stood at 15.93% in 2021, then grew by 3bps to 16.39% in 2022, then dropped by -20bps to 13.07% in 2023, then plummeted by -30bps to 9.09% in 2024, then skyrocketed by 83bps to 16.63% in 2025.
  • Per Business Quant, the three most recent readings for ABBV's Return on Capital Employed are 16.63% (Q4 2025), 9.4% (Q3 2025), and 11.32% (Q2 2025).